Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nurix TherapeuticsNRIX -0.71%59 Interest Coverage is 0 (At Loss) as of May. 2026. GuruFocus rates NRIX with a GF Score™ of 59/100 and a GF Value™ of $7.82 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 367 Biotechnology companies, Nurix Therapeutics ranks worse than 272479.29% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Nurix Therapeutics's
Operating Income
for the
three
months ended in May. 2026 was $-94.20 Mil. Nurix Therapeutics's Interest Expense for the
three
months ended in May. 2026 was $0.00 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Nurix Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Nurix Therapeutics's Interest Coverage or its related term are showing as below:
NRIX's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 104.07 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Nurix Therapeutics Interest Coverage Related Terms
Nurix Therapeutics Interest Coverage Historical Data
* Premium members only.
The historical data trend for Nurix Therapeutics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NRIX vs ATAI, SLS, VRDN: Interest Coverage Comparison
For the Biotechnology subindustry, Nurix Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nurix Therapeutics Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Nurix Therapeutics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
GuruFocus does not calculate Nurix Therapeutics's interest coverage with the available data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Nurix Therapeutics (NRIX) has a Interest Coverage of 0 (At Loss) as of May. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Nurix Therapeutics and its competitors. Over the past decade, Nurix Therapeutics' Interest Coverage has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, Nurix Therapeutics ranks #999999 out of 367 companies in the Biotechnology industry.
Is Nurix Therapeutics' Interest Coverage too high?
Nurix Therapeutics' current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, Nurix Therapeutics ranks #999999 out of 367 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nurix Therapeutics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nurix Therapeutics' Interest Coverage compare to ATAI and SLS?
According to the Biotechnology industry distribution chart, Nurix Therapeutics ranks #999999 out of 367 companies for Interest Coverage. This places Nurix Therapeutics in the lower half of its industry. The industry median Interest Coverage is 104.07. Historically, Nurix Therapeutics' own Interest Coverage has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.07, based on 367 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Nurix Therapeutics and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nurix Therapeutics's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nurix Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nurix Therapeutics (NRIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.82, compared to a current price of $25.26 — trading 223% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Nurix Therapeutics' overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Nurix Therapeutics (NRIX), the current Interest Coverage is 0 (At Loss) as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nurix Therapeutics (NRIX) Overvalued in 2026?
Based on GuruFocus' analysis, Nurix Therapeutics stock appears to be overvalued.
The current stock price of $25.26 is trading 223% above its estimated GF Value™ of $7.82.
GuruFocus considers Nurix Therapeutics to be Significantly Overvalued.
Key valuation signals for NRIX:
Interest Coverage: 0 (At Loss)
GF Value™: $7.82 vs. price of $25.26 (223% above fair value)
No single metric tells the full story. See the NRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
59GF Score
Get the complete analysis for NRIX
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRIX has been successfully added to your 
